Exudative age-related macular degeneration (AMD) is a major indication for the administration of
intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for
this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment.
Strategies for achieving a longer duration of pharmacological action are currently being developed. These
include the development of longer-acting drugs, and of novel technologies to increase the duration of action of
administered agents. This manuscript will review the novel drugs and technologies currently being developed for
achieving a longer-action pharmacotherapy for exudative AMD.
Keywords: Age related macular degeneration, long term, long acting, intravitreal therapy, anti-VEGF agents, pharmacotherapy.
Rights & PermissionsPrintExport